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Oxidative phosphorylationCytochrome c oxidase (COX) deﬁciencies are one of the most common defects of the respiratory chain found
in mitochondrial diseases. COX is a multimeric inner mitochondrial membrane enzyme formed by subunits
encoded by both the nuclear and the mitochondrial genome. COX biosynthesis requires numerous assembly
factors that do not form part of the ﬁnal complex but participate in prosthetic group synthesis and metal
delivery in addition to membrane insertion and maturation of COX subunits. Human diseases associated with
COX deﬁciency including encephalomyopathies, Leigh syndrome, hypertrophic cardiomyopathies, and fatal
lactic acidosis are caused by mutations in COX subunits or assembly factors. In the last decade, numerous
animal models have been created to understand the pathophysiology of COX deﬁciencies and the function of
assembly factors. These animal models, ranging from invertebrates to mammals, in most cases mimic the
pathological features of the human diseases.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria, ubiquitous organelles of eukaryotic cells, are the
main generators of cellular ATP and carry several important metabolic
reactions such as the tricarboxylic acid cycle (TCA), lipid β-oxidation
and oxidative phosphorylation (OXPHOS). Mitochondria also play
an active role in survival and death signaling and cellular calcium
homeostasis. Defects in mitochondrial function are associated with
numerous neurodegenerative diseases (Parkinson's, Alzheimer's and
Huntington's disease) and in particular with mitochondrial diseases.
Mitochondrial diseases are characterized by defects in the oxidative
phosphorylation (OXPHOS) systemwith an incidence of 1 in 5000 [1].
They are heterogeneous in nature, affecting multiple organs partic-
ularly those with higher energetic demands such as muscle and brain.
Mitochondria have their own genome which encodes for about 1% of
the total mitochondrial proteins, therefore, mitochondrial biogenesis
occurs as a result of a highly coordinated action between the nuclear
and the mitochondrial genome that requires the import of several
proteins into the mitochondria that are encoded by the nuclear
genome (reviewed in [2]). For this reason, mitochondrial diseases are
caused by mutations in mitochondrial genes, in nuclear genes
encoding for subunits of the respiratory chain complexes or in
genes coding for proteins involved in the nuclear–mitochondrial
communication (reviewed in [3]). This review focuses on defects in
cytochrome c oxidase (COX) or complex IV, one of the most common
defects of the OXPHOS system.ll rights reserved.2. Oxidative phosphorylation
The mitochondrial metabolic pathway converting substrates gen-
erated from glycolysis and β-oxidation into energy in the form of
ATP is known as oxidative phosphorylation (OXPHOS). The OXPHOS
system is composed of 5 multi-enzyme complexes (complexes I
through V) and two electron carriers, a quinone (coenzyme Q) and a
small heme containing protein (cytochrome c) that are located in the
inner mitochondrial membrane. These respiratory complexes are
formed by subunits encoded by both the mitochondria and the
nuclear genome with the exception of complex II which is entirely
encoded by the nuclear DNA. In this energy generating pathway, the
reducing equivalents NADH and FADH2 formed during TCA cycle and
β-oxidation enter into the electron transport chain (complexes I
through IV of the OXPHOS system) at the level of complex I (NADH:
ubiquinone oxidoreductase) or at the level of complex II (succinate
dehydrogenase) respectively. Electrons are subsequently transferred
to the non-protein electron carrier coenzyme Q and then to complex
III (ubiquinol:cytochrome c oxidoreductase or bc1 complex). The
second electron carrier, cytochrome c, acts as a bridge for the transfer
of electrons between complexes III and IV (cytochrome c oxidase).
Once the electrons have reached complex IV they are transferred to
molecular oxygen to form water. During the transfer of electrons
through the electron transport chain (ETC, complexes I–IV), protons
are translocated simultaneously from the matrix to the mitochondrial
intermembrane space by complexes I, III and IV. This proton trans-
location creates an electrochemical gradient that is utilized by
complex V (ATPase synthase) to generate ATP with the concomitant
translocation of protons back into the matrix. In the last few years,
studies on the respiratory complexes have revealed that they are
assembled in large structures or supercomplexes to form a functional
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“respirasomes” allows for a more efﬁcient substrate channeling, in-
cluding electron transfer and proton translocation, thus minimizing
the formation of free radicals by reducing the direct transfer of elec-
trons to oxygen [5]. Nevertheless, the electron transport chain is one
of the major pathways leading to the production of reactive oxygen
species (ROS) in the cell.
3. Cytochrome c oxidase
3.1. Structure and function
Cytochrome c oxidase (COX) is the terminal component of the
electron transport chain and catalyzes the transfer of electrons from
cytochrome c to oxygen. The mammalian enzyme is a 200 kDa com-
plex composed of 13 subunits encoded by both the mitochondrial
(COX1, COX2 and COX3 subunits) and the nuclear genome (COX4,
COX5a, COX5b, COX6a, COX6b, COX6c, COX7a, COX7b, COX7c and
COX8 subunits) [6,7]. The large catalytic subunits are encoded by the
mitochondrial DNA (mtDNA) and constitute the core of the enzyme.
The small peripheral structural subunits surrounding the catalytic
core are encoded by the nuclear DNA.
COX is active as a dimer and requires several prosthetic groups for
catalytic function: 2 hemes (a and a3), two copper centers (CuA and
CuB), zinc and magnesium. Tsukihara and collaborators resolved the
crystal structure of the metal sites and the whole complex with the 13
subunits of the bovine heart cytochrome oxidase at 2.8 Å resolution.
Both heme a and the binuclear center a3-CuB are located in COX1
(subunit 1) whereas the binuclear CuA center is located in COX2
(subunit 2). A Zn2+ ion is in COX5b on the matrix side of the complex
and a Mg2+ ion is in proximity to the a3-CuA site between COX1 and
COX2. Additionally, complex IV can also bind calcium and sodium ions
[7,8].
During catalysis, the electrons from reduced cytochrome c are
transferred consecutively to the CuA site, to heme a, and then to
oxygen in the heme a3-CuB center producing water. This transfer of
electrons is coupled to the translocation of 2 protons from the matrix
into the intermembrane space in each cycle [9–11].
The catalytic function related to the redox chemistry is carried out
by both COX1 and COX2 subunits whereas the proton translocation
activity appears to be associated to the COX3 subunit [9]. The function
of the peripheral structural subunits in the eukaryotic enzyme is still
not completely understood, since the catalysis is carried out by the
mitochondrial encoded subunits. The bacterial complex functionswith
only the 3 catalytic subunits. The nuclear-encoded subunits appear
to play a role in the regulation and stability of the fully assembled
complex [12,13].
3.2. Regulation of enzyme activity
As a rate limiting enzyme in the OXPHOS system, COX activity is
subjected to regulation by a gamut of molecules to meet the energetic
demands of the cell including hormones, membrane lipids and second
messengers. For example: thyroid hormone regulates COX activity
by binding to COX5a [14] and oxidized cardiolipin and nitric oxide
inhibit COX activity [15,16]. Moreover, COX activity is also regulated
by allosteric inhibition/activation by ATP/ADP and by phosphoryla-
tion of different subunits by kinases like c-SRC, cAMP dependent
protein kinase, PKCε and PKCδ [17–23].
Another level of regulation of COX activity appears to be mandated
by the existence of some tissue-speciﬁc, species-speciﬁc isoforms or by
the protein content of some of the small subunits in a tissue/cell type.
In humans, isoforms for subunits COX4, COX6a, COX6b, COX7a and
COX8 have been described. COX6a and COX7a have liver (ubiquitous)
and heart speciﬁc isoforms; COX4 has a lung speciﬁc isoform [24] and
COX6b a testis speciﬁc isoform. In the case of species-speciﬁc isoforms,isozymes for COX8 in bovine, dog and rat are not found in human,
sheep and rabbit [18,25–27]. In yeast (Saccharomyces cerevisiae), there
are two Cox5 isoforms (homolog of human COX4)whose expression is
dependent on the environmental oxygen [28]. During normoxia, the
Cox5a isoform is expressed whereas in low oxygen the expression
switches to the Cox5b isoform. This switch confers higher enzymatic
efﬁciency during hypoxia [29]. Similarly, this homeostatic mechanism
and higher enzymatic efﬁciency is also observed in mammalian cells.
In response to hypoxia, an isozyme switch of COX4-1 for COX4-2
occurs and ismediated by Hif-1 [30]. In the case ofmammalian COX5b,
no isoforms have been reported albeit this subunit can modulate COX
activity by varying its content in relation to the whole complex [31].
Moreover, COX5b is required for assembly and stability of complex IV
[13].
3.3. Enzyme biogenesis
Although great advances have been made on the understanding of
the mechanism of COX biogenesis in the last 10 years, this process is
still not completely unraveled. What is known about this complicated
mechanism has been elucidated in its majority either from systematic
studies in yeast, using mutant strains defective in COX assembly or
from studies in cell lines derived from patients with COX deﬁciencies.
Studies in yeast revealed that the COX assembly process requires
more than 30 auxiliary proteins, encoded in the nuclear genome, that
do not form part of the ﬁnal assembled complex. Recent ﬁndings, not
described in this review, imply that not all the COX assembly factors
have been already discovered even in yeast [32]. These auxiliary
proteins or assembly factors play an important role in several aspects
related to heme a biosynthesis [33]; copper delivery and homeostasis
[34]; transport of nuclear-encoded subunits across the mitochondrial
membrane; and translation, membrane insertion and maturation of
mitochondrial encoded subunits [35]. The function of some of this
newly identiﬁed assembly factors, many with unknown mammalian
homologues to date, are described in more details in recent reviews
[36–38].
Among the accessory proteins that participate in COX assemblywith
clinical implications in humans are COX10, COX15, Surf1, LRPPRC, SCO1
and SCO2. The functions of COX10 and COX15 are related to heme a
biosynthesis. Hemea is a uniquemolecule exclusive of COX that is found
in two chemical forms, the awhich is a low-spin heme and the a3 which
is a high-spin heme. The ﬁrst step of heme a synthesis starts with the
conversion of heme b into heme o which requires the farnesylation of
the vinyl group present in carbon 2. This step is catalyzed by COX10, a
farnesyl transferase [39]. Then heme o is converted to heme a by COX15
and a monooxygenase, yet to be identiﬁed in humans [40]. These en-
zymes hydroxylate themethyl group in carbon 8which is subsequently
oxidized into a formyl group [41–43].
The function of Surf1, in spite of numerous studies remains elusive.
However, Surf1 is known to play a role in the early assembly steps
of COX. In the protobacteria Rhodobacter sphaeroides Surf1 assists in
the insertion of heme a3 into COX1 and in the maturation of the heme
a3-CuB center [44]. The Surf1 yeast homologue, Shy1, has been shown
to genetically interact with the COX1 translation machinery. These
include mss51 and COX14, proteins required for COX1 translation in
yeast [45]. Additionally, Shy1 remains associated with COX subas-
sembly intermediates that are able to interact with complex III to form
supramolecular arrangements [46]. Interestingly, a recent report on
the analysis of tissues from patients with Surf1 deﬁciency suggests
that this protein has an additional role in copper homeostasis [47].
SCO1 and SCO2 participate in copper delivery to COX, cellular copper
homeostasis and redox signaling [48–50]. These two copper chaperones
albeit sharing high similarity, do not have overlapping functions but
rather act in combination [51]. The copper delivery to the two metal
centers in COX (CuA located in COX2 and CuB located in COX1) is carried
out by several proteins. COX17 another copper chaperon delivers the
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pates in the formation of the CuB center whereas SCO1 and SCO2
participate in the formation of the binuclear CuA center (reviewed in
[52]). Additional roles for SCO1 and SCO2 have been recently proposed
[47,53]. Stiburek and colleagues showed that SCO1 interacts with the
fully assembled complex in human muscle mitochondria, and that in
SCO1 patients, the mutant SCO1 was associated with subassembly
intermediates containingCOX2. These results suggest a SCO1 is involved
in a different posttranslational step in the maturation of COX2 other
thanor additional to copperdelivery [47]. The incorporationof copper to
COX2 was thought to occur while the subunit was embedded in the
membrane but prior to its incorporation into the complex. Leary et al.
found that although both SCO proteins are required for CuA site metal
loading, SCO2 alone is required for COX2 synthesis and additionally acts
as a thiol reductase of SCO1 [53].
3.3.1. Assembly intermediates
The assembly of COX has been characterized in numerous cell lines
or tissues from patients with defects in the assembly proteins using
blue native gel electrophoresis [54]. This technique permitted the
separation of respiratory complexes in their active native conforma-
tion, allowing the detection of subassembly intermediates and of
supramolecular interactions [55]. Using information provided by this
technique, Nijtmans and collaborators proposed a sequential assem-
bly process that starts with COX1 and the addition of its respective
prosthetic groups (heme a and CuB center). This constitutes the ﬁrst
subassembly intermediate or S1. Then COX4 is added to form the S2
intermediate to which COX2, COX3, COX5a, COX5b, COX6b, COX6c,
COX7a, COX7c and COX8 subunits are subsequently added to form the
S3 intermediate. Lastly, COX6a and COX7b join S3 to form the ﬁnal
intermediate S4. This last intermediate constitutes the monomeric
form of COX that subsequently dimerizes to form the active com-
plex [56,57]. Further analysis of different tissues from patients with
Surf1 and SCO2mutations prompted Stiburek et al. to reﬁne Nijtmans'
model. In this analysis, the authors conﬁrmed that COX4 and COX5a
are in a preexisting subcomplex [58] previous to their addition to the
S1 intermediate. The addition of COX4/COX5a subcomplex occurs
after the incorporation of prosthetic groups in COX1 but previous to
the addition of COX2 [59].
The assembly of COX as well as other respiratory complexes has
been recently reviewed by Fernandez-Vizarra and colleagues [60].
4. Mitochondria and cytochrome c oxidase in neurons
In addition to mitochondrial diseases, mitochondrial malfunction
and defects in respiratory complexes have been associated with many
neurodegenerative diseases and aging. This section highlights the
importance of this organelle not only in metabolism but also in
neuronal plasticity. Mitochondria have a wide distribution in neurons.
They are present in the cell body and in functional domains with high
energetic requirements during neuronal activity such as dendrites,
nodes of Ranvier, synapses and axonal growth cones (reviewed in
[61]). The wide distribution of these organelles in neurons is achieved
by mitochondrial transport through actin and microtubules tracks.
Mitochondria are indispensable to provide the energy necessary for
synaptic transmission and play an important role on neurotransmit-
ters release and uptake, calcium buffering, vesicle cycling in pre-
synaptic terminals, repolarization after depolarizing stimulation, and
growth cone formation. Recent studies have showed that mitochon-
drial biogenesis (including mtDNA replication and fusion and ﬁssion
events) occurs in distal axons independently of the cell body [62].
Neurons have compartmentalized protein synthesis. Although the
majority of the protein synthesis occurs in the cell body, there are
functional regions distal from the soma (axons, dendrites and synaptic
terminals) that require fast protein synthesis [63,64]. This compart-
mentalization plays a crucial role on synaptic plasticity required forneuronal activity. Kaplan's group [64] found that those mRNAs that
are transported for local protein synthesis encode a wide variety of
proteins of diverse functions i.e. cytoskeleton proteins, translation
machinery proteins (ribosomal and translation factors), molecular
motors proteins and metabolic enzymes [64]. Additionally, a high
abundance of mRNAs (about 25%) encoding mitochondrial proteins
and chaperons has been found in the axon terminal of the squid giant
axon [65]. The authors showed that protein synthesis in the axon
terminal was necessary for mitochondrial function and axonal main-
tenance. In a series of elegant experiments, Hillefors and colleagues
[66] showed that inhibition of axonal protein synthesis resulted in
axonal retraction, altered mitochondrial membrane potential and im-
paired restoration of axonal ATP levels following membrane depolar-
ization. In contrast,whenmitochondrial protein synthesiswas blocked
by chloramphenicol treatment, none of the previous effects were
observed [66].
COX activity has been proposed to be a good indicator of metabolic
capacity required for neuronal function in neurons.Wong-Riley's group
[67,68] had extensively studied the transcriptional regulation of the
mitochondrial andnucleargenome inCOXbiosynthesis duringneuronal
activity. They have shown that neuronal stimulation upregulated
mRNAs for all the COX subunits after 5 h whereas the blocking of
neuronal activity with tetrodotoxin produced a downregulation of COX
transcripts in a time differential manner in primary rat visual cortical
neurons. Mitochondrial encoded COX mRNAs were downregulated
two times faster (2 days) than the nuclear-encoded COX mRNAs
(4 days). These changes in mRNA levels also were reﬂected at the
protein and at the enzyme activity levels. During neuronal activity,
membrane repolarization after an excitatory stimulus requires higher
energy expenditure in neurons. The investigators propose that the
availability of mitochondrial subunits upon neuronal stimulation play a
central role in regulating cytochrome c oxidase levels and activity in
neurons [67].
Dhar and collaborators [68] proposed that the tight coupling be-
tween the energetic metabolism and the neuronal activity, regulated at
the level of transcription, is reached by having a common transcription
factor [68]. The authors showed that both AMPA glutamate receptor
subunits and COX subunits are regulated by the same transcription
factor, nuclear respiratory factor 1 (NRF-1). Moreover, knocking down
NRF-1 prevented the upregulation of GluR2 (AMPA glutamate receptor
subunit that regulates the calcium permeability of the receptor) and
COX subunits during synaptic stimulation [69].
Recently, an additional level of regulation of COX biogenesis in
neurons has been identiﬁed. This novel mechanism involves the pres-
ence ofmicroRNAs in axons anddendrites that can repress translation of
speciﬁc mRNAs or target them for cleavage. Like mRNAs, microRNAs
have been shown to be also located in different neuronal compartments
[70]. Aschraﬁ et al. discovered that COX4mRNA levelswere regulated in
axonal terminals by a speciﬁc microRNA (MiR-338) therefore control-
ling the local mitochondrial respiration and ATP levels [71].
5. Cytochrome c oxidase deﬁciency in patients
COX deﬁciencies in humans comprehend a wide variety of dis-
orders and the pathological features and genotype have been exten-
sively reviewed [72–77]. This section summarizes some of the features
of the COX deﬁciencies, includes some new ﬁndings and discusses
someof the pathological phenotypes ofmutations in COX subunits and
assembly factors with high clinical relevance. Table 1 shows a sum-
mary of the genes associated with COX deﬁciencies and the different
clinical presentations.
Genotypically, isolated COX deﬁciencies could arise from muta-
tions in any of the 3 subunits encoded in the mtDNA, from any of the
10 structural subunits encoded in the nucleus or from mutations
in any of the assembly factors. Phenotypically, all these possibilities
create a wide variation on the clinical symptoms that could affect
Table 1
Gene defects associated with cytochrome c oxidase deﬁciencies in humans.
Mutated gene Function Clinical features Reference
mtDNA-encoded subunits
MTCOX1 Catalytic core Encephalopathy
Sideroblastic anemia
Myoglobinuria
Motor neuron disease
MELAS-like syndrome
[137]
[81]
[138]
[139]
[140]
MTCOX2 Catalytic core Myopathy
Encephalopathy
Multi systemic disease (bilateral cataracts, sensorineural hearing loss,
myopathy, ataxia) and metabolic acidosis
[141]
[80]
[142]
MTCOX3 Catalytic core MELAS
Encephalopathy
Leigh-like syndrome
Exercise intolerance and rhabdomyolysis
[143]
[82]
[144]
[142]
Nuclear-encoded subunits
COX6b1 Structural subunit Encephalopathy [84]
Assembly factors
Surf1 Unknown Assists in early CIV assembly Leigh syndrome [85,86]
COX10 Heme a biosynthesis Leukodystrophy
Tubolopathy
Hypertrophic cardiomyopathy
Leigh syndrome
Leigh-like syndrome
[97]
[88]
[98]
COX15 Heme a biosynthesis Cardiomyopathy
Leigh syndrome
[99]
[100,101]
SCO1 Copper delivery and homeostasis Hepatopathy
Metabolic acidosis
Hypertrophic cardiomyopathy
Encephalopathy
[96]
[47]
SCO2 Copper delivery and homeostasis Hypertrophic cardiomyopathy
Encephalopathy
[94]
[95]
LRPPRC COX1 and COX3 mRNA stability French–Canadian Leigh syndrome [91]
[92]
TACO1 COX1 translational activator Slowly progressive Leigh syndrome [104]
FASTKD2 unknown Encephalopathy [102]
MELAS: mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes.
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deletions, duplications or mutations in any of the tRNA genes can also
affect COX function along with defects in complexes I, III and V. This is
the case of diseases such as progressive external ophthalmoplegia and
Kearns–Sayre syndrome [78]. One of the pathogenic characteristic of
mtDNA deletions or tRNA point mutations is the presence of a mosaic
pattern of COX positive and COX negative ﬁbers in muscle biopsies as
well as the presence of ragged-red ﬁbers (RRF) which are due to the
presence of an increased number of mitochondria that stain red with
Gomorri Trichrome [79]. This increase in mitochondrial mass or mito-
chondrial biogenesis is believed to be the result of a compensatory
mechanism for respiratory defects.
5.1. Mutations in COX subunits
Few COX deﬁciencies involve mutations in the mitochondrial en-
coded subunits [80–83]. The clinical presentations of such mutations
encompass myopathy, sideroblastic anemia, amyotrophic lateral sclero-
sis (ALS)-like syndrome, encephalomyopathy and MELAS (mitochon-
drial myopathy, encephalopathy, lactic acidosis and stroke-like
episodes) [3,74]. The muscle of patients with mutations in the mtDNA-
encoded COX subunits showed large amounts of COX negative ﬁbers
without RRF [73]. These mtDNA mutations could affect a single tissue
(myopathies) or multiple systems (MELAS and encephalomyopaties)
and the severity of the COXdeﬁciency could vary in different tissues. The
difference in severity and tissue speciﬁcity remains elusive although
heteroplasmic load of the mtDNA mutation (coexistence of wild type
and mutant mtDNA) and threshold effect of a particular mutation
(amount ofmutantmtDNA required to cause a defect, usually very high)appear to be the main culprits. In terms of defects derived from nuclear
mutations, the differences in tissue speciﬁcity could be explained by
differences in the levels of certain subunits or assembly factors, presence
of speciﬁc isozymes, speciﬁc regulatory mechanisms (phosphorylation
and allosteric regulation) or by differential availability of cofactors.
Mutations in the nuclear-encoded subunits were not found for
many years in patients with COX deﬁciency leading to the idea that
these mutations were incompatible with live. Recently, Massa and
colleagues [84] described two patients (siblings from cousin parents
in third degree) suffering from severe infantile encephalopathy with
COX deﬁciency. Both patients were homozygous for a mutation in the
COX6b1 gene [84]. Because this was the ﬁrst report of a mutation in a
nuclear-encoded COX subunit, the pathogenicity of the mutation was
functionally validated in yeast and indeed it caused COX deﬁciency.
Further analysis of these patient tissues showed that even though the
mutant COX6b1 protein was synthesized, it failed to be incorporated
into the holoenzyme, therefore causing the enzymatic defect [84].
5.2. Mutations in COX assembly factors
Themajority of the genetic defects related to COX deﬁciencies have
been found in nuclear genes coding for auxiliary proteins. The ﬁrst
identiﬁed COX deﬁciency with a nuclear origin was Leigh syndrome
(LS), a fatal subacute neurodegeneration with an early onset affecting
the whole body [85,86]. LS patients die between 6 months to 12 years
of age. The typical pathology of Leigh syndrome includes the presence
of bilateral symmetric necrotic lesions in subcortical areas of the
brain (brain stem, basal ganglia and thalamus) that develop into
ophthalmoparesis, nystagmus, ataxia, dystonia and optic atrophy.
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ation and vascular proliferation [87]. The residual levels of COX activity
observed in LS patients range from 10 to 25% of control values with no
apparent correlations in terms of severity and tissue speciﬁcity. The
gene responsible for LS in cases associated with COX deﬁciency was
the assembly factor Surf1. However, not all the mutations in this gene
produced Leigh syndrome, some Surf1 patients did not develop the
characteristic neurodegenerative lesions. In some cases, the pathology
of Leigh syndrome has been associated with mutations in the COX10
gene or with mutations in the mtDNA [88,89]. Moreover, LS can result
from defects in other genes altering energetic metabolism such as
pyruvate dehydrogenase, NADH:ubiquinone oxidoreductase (com-
plex I) or ATP synthase (complex V) [90].
A less severe form of LS is the French–Canadian Leigh syndrome
(FCLS, exclusive of the Charlevoix and Saguenay-Lac-St. Jean region of
Quebec). Clinical presentations of this form include mild regression of
psychomotor skills and a fatal lactic acidosis with death occurring
between 3 and 10 years of age. In this disorder, the tissues mostly
affected are brain (basal ganglia) and liver [91]. Mootha et al. identiﬁed
LRPPRC (leucine-rich pentatricopeptide repeat cassette) as the gene
responsible for this disease [92]. LRPPRC is a homologue of the yeast
P309, another COX assembly factor, which is required for the expres-
sion of COX1 by assisting in the stability and translation of COX1mRNA.
Analysis of LRPPRC mRNA levels in different tissues from patients with
FCLS revealed that those tissues that weremostly affected (higher COX
deﬁciency) had the lowest levels of expression [93]. Conﬁrming the role
of LRPPRC as an mRNA stabilizing protein, studies in FCLS patients
showed a severe decrease on the levels of COX1 and COX3 mRNAs (23
and 30% of control levels respectively) [93].
Another COX deﬁciency characterized by hypertrophic cardiomy-
opathy with encephalopathy also with an early onset is due to muta-
tions in the copper related assembly factor SCO2. Although the COX
deﬁciency was more severe in cardiac and skeletal muscle, autopsy
analysis of the brain revealed spongiform neurodegeneration in
midbrain, pons and medulla accompanied by gliosis and microglia
proliferation in the thalamus, but lacked the typical LS lesions [94,95].
Mutations in the other copper chaperone, SCO1 have been associated
with completely different phenotypes. Valnot and collaborators [96]
reported two neonate cases, the ﬁrst one with severe metabolic
acidosis and with hepatic failure consisting in microvesicular steatosis
(lipid accumulation) and enlarged liver. The patient died at 2 months
of age. A severe COX deﬁciency in liver and muscle (less than 1% of
control values) was determined in postmortem tissues. The second
case was a sibling born in early pregnancy that also presented with
metabolic acidosis andneuronal involvement anddied at 5 days of age.
In both cases, the defect mapped to the SCO1 gene. The patients were
compound heterozygous [96]. A third case of SCO1 defect was just
recently reported [47]. This last patient presented with an early onset
of hypertrophic cardiomyopathy accompanied by encephalopathy and
hepatomegalia and died at 6 months of age. Ultrastructural analysis of
the cardiac tissue showed accumulation of abnormal mitochondria of
varying sizes, containing hemidense deposits. The liver had micro-
vesicular steatosis and the muscle lacked ragged-red ﬁbers [47].
Defects in the heme a biosynthetic pathway lead to different clinical
presentation also with fatal outcome early on life (months to 2 years of
age). The ﬁrst COX10 mutation reported by Valnot et al. was found in a
pediatric patient suffering fromataxia,muscleweakness, hypotonia and
pyramidal syndrome, leukodystrophy and proximal tubolopathy ac-
companied by elevated lactate in both cerebrospinal ﬂuid and blood
[97]. Other patients with mutations in COX10 presented with anemia,
sensorineural deafness and hypertrophic cardiomyopathy [88]; with
anemia and Leigh syndrome [88]; and with Leigh-like syndrome [98].
The levels of COX activity in COX10 patients ranged from 5 to 25% of
control, depending on the tissues analyzed. Also few patients with
COX15 defects have been documented. The ﬁrst patient studied by
Antonicka et al. had lactic acidosis, hypotonia and seizures and afterdeveloping amassive biventricular cardiomyopathydied before theﬁrst
month of age [99]. The residual COX activity in this patient ranged from
7 to 25% of control values on the tissues analyzed. Another COX15
pediatric patient presented a completely different clinical phenotype. At
7 months of age this second patient had hypotonia, nystagmus, motor
regression, retinopathy and microcephaly, increased lactate levels in
blood, and cerebrospinal ﬂuid and at 1 year of age had developed the
typical Leigh syndrome lesions. The patient died before the fourth year
of age. COX activity in primary cultured ﬁbroblast was undetectable
[100]. The third COX15patientwas also diagnosedwith Leigh syndrome
but with a very slow progression of the disease and only showing
skeletal muscle and brain involvements. At the time of the report the
patient was 16 years old. Initially lactate levels were elevated but pro-
gressively went down to normal range while other features remained
unchanged. The COX deﬁciency in muscle and ﬁbroblast (42 and 22% of
control values respectively)was not as severe as in the case of the other
twoCOX15patients perhaps accounting for the slowprogressive clinical
phenotype [101].
A report of two patients with an early onset of mitochondrial
encephalopathy presenting asymmetrical brain atrophy, convulsions,
hemiplegia and psychomotor developmental delay associated with low
levels of cytochrome c oxidase activity in skeletal muscle showed that
the defect mapped to the FASTKD2 (fas activated serine–threonine
kinase domain 2) gene [102]. Although the function of FASTKD2 is not
known, this protein appears to be involved in apoptosis. Preliminary
results showed no abnormalities in COX assembly in the patient's
muscle as assessed by blue native gels [102]. Further investigations are
required to determine if the ablation of the FASTKD2 directly affects
COX activity or if this effect is a consequence of a more generalized
dysfunction.
The assembly factors described above along with mtDNA genes
constitute candidate genes screened to diagnose the causes of COX
deﬁciency in patients. Recently, another yeast assembly gene with a
human homolog that has been proposed as a screening candidate for
COX deﬁciencies is COX18, which is required for the insertion of COX2
into the inner mitochondrial membrane. Unfortunately, mutational
screening of COX18 gene in a large cohort of patientswith an unknown
cause of COXdeﬁciency andwheremutations in other candidate genes
were already ruled out, failed to reveal any sequence abnormality for
COX18 suggesting that mutations in this gene could be incompatible
with life or not as frequent [103].
As mentioned earlier, not all the steps of COX biogenesis and
assembly factors discovered in yeast have been identiﬁed in humans.
This is the case of factors related to mtDNA transcription and trans-
lation. There are fundamental differences between yeast and humans
such as the presence of introns in the mtDNA and the presence of 5′
UTRs in mitochondrial mRNAs in yeast. Additionally, yeast mitochon-
drial mRNAs require translational activators that recognize their 5′
UTRs and promote translation. These differences suggest different
mechanisms ofmitochondrialmRNA translation and perhaps different
type of factors to accommodate the lack of mRNA regulatory elements
found in humans. A newhumanCOX assembly factorwas identiﬁed by
Shoubridge's group while studying a COX deﬁcient patient with Leigh
syndrome with a slow progression of the disease [104]. The authors
found that in this particular patient the COX defect was due to a
mutation in the CCDC44 gene that impaired COX1 protein synthesis.
This gene encodes a protein, conserved in bacteria, that functions as a
translational activator of COX1, and therefore was renamed TACO1
after its function [104]. This recent ﬁnding perhaps opens the door to
the study and search of newCOX assembly factors yet to be discovered
in humans.
6. Animal models of cytochrome c oxidase deﬁciency
This section describes the different animal models for isolated COX
deﬁciencies created by deletion or knock down of COX subunits and
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in the mitochondrial ﬁeld to the understanding of the pathophysio-
logical mechanisms of mitochondrial diseases and the development of
better therapeutic approaches. Fig. 1 summarizes the existing animal
models, the different clinical phenotypes and the genes responsible
for COX deﬁciencies observed in humans. Information of animal
models that include additional defects of the oxidative phosphoryla-
tion system can be found in recent reviews by Torraco et al. [105] and
Vempati et al. [106]. Animal models with defects in the mtDNA can be
found in reviews by Kahn et al. [107] and Tyynismaa and Suomalainen
[108].
6.1. Animal models with defects in COX subunits
Inmice, all fetal tissues express the COX6a liver isoform (COX6a-L).
As mice develop, the liver isoform is gradually replaced only in heart
and muscle by the heart isoform (COX6a-H). In the cardiac tissue, this
isoform switch is completed when mice are 28 days old [109]. To get
insights into the function of the heart isozyme, Radford et al. [110]
created a knockout (KO)mouse. The COX6a-H nullmouse developed a
subtle myocardial diastolic dysfunction with no apparent ultrastruc-
tural abnormalities. The disruption of COX6aH affected neither fertility
nor life span. The KO mice had a COX deﬁciency of about 23% com-
pared to control animals in cardiac tissue and the levels of the fully
assembled complex were signiﬁcantly decreased. The authors con-
cluded that the COX6a-H subunit is required for proper assembly and
stability of the complex [110].
Liu and colleagues found the levymutant when screening temper-
ature sensitive Drosophila melanogaster mutants. The levy ﬂies suf-
fered from reversible paralysis in response to increased temperature
(38 °C). For young ﬂies (2 days old) the paresis occurred within 5 minFig. 1. Gene defects associated with cytochrome c oxidase deﬁciencies in humans and exis
subunits or assembly factors associated with COX deﬁciencies are labeled in red. The differen
the ﬁgure: mouse, zebraﬁsh, Drosophila, and C. elegans.of exposure to increased temperature and the movement recovery
occurred within 30 min. In contrast, older ﬂies (1 month old) para-
lyzed faster, within 30 s and were slower in recovering movement
(3 h). The levymutation was mapped to the COX6a gene and caused a
progressive COX deﬁciency with premature death. The life span of the
mutant ﬂies was about half of the wild type. Other phenotypes in-
cluded motor dysfunction as well as a spongiform type of neurode-
generation in the brain and optic lobes. This is the ﬁrst Drosophila
model with a mutation in a COX structural gene that rather than
lethality caused a mitochondrial encephalomyopathy [111].
A knock down (KD) of the structural subunit COX5awas created by
Baden et al. in Danio rerio (zebraﬁsh) [112]. The zebraﬁsh constitutes
a convenient animal model to study events during early development
because of the transparency of the embryonic and larval stages and
their extra uterine development. Disruption of translation of the
COX5a mRNA was achieved using antisense morpholino oligonucleo-
tides allowing the study of dosage dependence phenotype. The KD
ﬁsh had about 50% COX deﬁciency when compared with control
animals that led to a series of developmental defects (small rostral–
caudal axis, impair gut development, microphtalmia, unabsorbed yolk
sac and abnormal cephalic shape). All these pathological features
resulted in early death (about 7 days after fertilization). In addition,
the COX5a KD ﬁsh had cardiac pathology although no apoptotic cells
were observed in this tissue. Neurological abnormalities were also
observed in this COX deﬁcient ﬁsh. Neurodegeneration was observed
in brain and neuronal tube in conjunction with peripheral neuropathy
were secondary motoneurons were severely impaired [112].
Recently, Suthammarak et al. knocked down subunits COX4 and
COX5a by RNAi in Caenorhabditis elegans [113]. These two subunits
are involved in the allosteric regulation of COX. The KDworms showed
developmental delay (taking an extra day to reach adulthood),ting animal models. Clinical pathologies associated with mutations in respective COX
t animal models created for a corresponding protein or mitochondrial DNA are shown in
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life span (12–14 days compared to 17 days for controlworms). The COX
deﬁciency obtained in the nematodes after knocking down either
subunit was less than 50% of control values. Moreover, the absence of
these subunits affected also complex I activity although the protein
levels of the fully assembled complex I were not altered. Additionally,
the formation of supercomplexes containing COX was also affected
[113].
Using a mitochondrial targeted endonuclease to the germ line, Xu
and colleagues created a Drosophila model carrying a homoplasmic
mutation in the mitochondrial COX1 gene [114]. The mutant ﬂies
displayed growth retardation, with progressive neurodegeneration
and myopathy with locomotor impairment resulting in a severe
reduction in their life span [114].
6.2. Animal models with defects in COX assembly factors
6.2.1. Surf1
To study Leigh syndrome, the group of Zeviani has generated two
KO mice for the COX assembly factor Surf1. The ﬁrst model was
obtained by disrupting the gene by targeted insertion of a neomycin
cassette and replacement of exons 5 to 7. This genetic disruption
caused embryonic lethality in the majority of the KO mice obtained.
Those KO mice that survived presented a wide variation on their life
span with the males being more affected and the majority dying
within the ﬁrst two months of age. The severity of the COX deﬁciency
varied among the tissues being higher in muscle and liver and lower
in heart and brain. Surf1 null mice had decreased muscle strength and
deﬁcit inmotor skills. Ultrastructural analysis ofmuscle tissue showed
accumulation of enlarged abnormal mitochondria in subsarcolemmal
area. Surprisingly, the Surf1 null mouse did not show any apparent
neurological abnormalities. Cortex, hippocampus and thalamic
regions were comparable to control animals. Morphological features
of neurons in common oculomotor and red nuclei (regions frequently
affected in Leigh syndrome) appeared normal in KO mice [115]. To
create the second animal model the authors only disrupted the last
portion of the Surf1 gene (exon 7). The COX deﬁciency in the second
model was comparable to the ﬁrst one but no embryonic lethalitywas
obtained. Moreover and unexpectedly, these animals had a prolonged
life span (about 5 months longer than controlmice) but again this new
model failed to show any neurodegenerative pathology. The reasons
for increased longevity were unexplained although the same pheno-
type was observed in CNS speciﬁc Surf1 knockdown in Drosophila. The
constitutive Surf1 knockout caused embryonic lethality in the fruit ﬂy
[116]. To produce a neurological phenotype and test for the sensitivity
of COX deﬁcient neurons to toxic stimulus, Surf1 KOmicewere treated
with kainic acid (glutamate agonists that induces Ca++ excitotoxi-
city). Kainic acid exposure produces epilepsy due to the stimulation of
AMPA glutamate receptors that leads to Na+ inﬂux, membrane
depolarization and consequently a massive Ca++ inﬂux through
NMDA receptors. This cascade alters cellular homeostasis and induces
neuronal death [117]. There was no difference in the frequency,
duration and severity of the seizures or mortality rate between the
Surf1 KO and control animals treated with kainic acid. Surprisingly, in
the surviving animals treated with kainic acid no signs of neuronal
degeneration were observed in the Surf1 KO mice when compared to
the surviving controls. Moreover, calcium induced apoptosis was
absent in KO mice whereas it was prominent in control mice.
Apparently, this apoptosis resistance was due to a reduced increase
of the intracellular and mitochondrial calcium levels in the Surf1
deﬁcient neurons [118].
A zebraﬁsh model for Surf1 was created by knocking down gene
expression with morpholino oligonucleotides by Baden et al. The
authors obtained the same phenotypical abnormalities described
above for the COX5a KD by knocking down Surf1 in ﬁsh (small
rostral–caudal axis, abnormal head shape, small eyes, underdevel-oped intestinal track and unabsorbed yolk sac) that resulted in early
death [112].
As mentioned earlier, ubiquitous knockdown of Surf1 in Droso-
phila caused impaired larval development and lethality whereas
the neuron speciﬁc KD bypassed this lethality. The neuron speciﬁc
Surf1 KD ﬂies reached adulthood and did not present evident signs
of neurodegeneration albeit they had abnormal photo-behavior
responses [116]. Recently, Fernandez-Ayala et al. tested in the Dro-
sophila Surf1 KD model a new strategy to bypass the COX defect that
consisted in expressing the alternative oxidase enzyme (AOX) from
Ciona intestinalis to transfer electrons directly from coenzyme Q to
oxygen. The tunicate enzyme, not found in vertebrates, was able to
circumvent the lethality of the fruit ﬂy Surf1 KD [119].
6.2.2. COX17
Deletion of the copper chaperone COX17 in mouse by Takahashi et
al. showed that this protein is indispensable not only for COX activity
but also for embryonic development and the KO mice died between
E8.5 and E10 [120]. These results indicate that functionally relevant
mutations in the COX17 gene are incompatible with life and to date
mutations in this gene have not been found in humans.
6.2.3. COX10
Conditional ablationof COX10 by theCre-loxP systemhas allowedus
to create tissue-speciﬁc models of COX deﬁciency in muscle, liver and
brain. To ablate this gene, loxP sites were introduced ﬂanking exon 6,
which encodes part of the active site of the enzyme. Disruption of
the ﬂoxed gene using the Cre recombinase driven by the myosin light
chain promoter allowed the creation of amyopathymousemodel [121].
The myopathy mouse had a progressive severe COX deﬁciency already
manifested at 1 month of age (13% of control values of COX activity in
muscle), although no signs of myopathy were observed. Muscles were
able to contract at forces similar to control animals andmyopathyc signs
were observed at approximately 3 months of age. The COX deﬁciency
progressed with age, showing a mosaic pattern mimicking mitochon-
drialmyopaties observed in patients and endedwith an early death. The
COX10 KO females were more affected than the males, having shorter
life span and pronounced exercise intolerance [121].
In search for mitochondrial disease treatments, we induced mito-
chondrial biogenesis, a natural compensatory mechanism observed
in many mitochondrial diseases, in the COX10 KO myopathy model.
The stimulation of mitochondrial biogenesis by induction of PGC-1α
(peroxisome proliferator activator receptor γ co-activator-1α) was
achieved by either genetic manipulation (PGC-1α overexpression in
skeletal muscle), bezaﬁbrate treatment (PPAR panagonist) or exercise
training and showed that increased mitochondrial mass in all cases
ameliorated the onset of myopathy and extended the life span of the
COX10 KO mice [122,123].
A mitochondrial hepatopathy mouse model was created by
ablating the ﬂoxed COX10 gene with Cre recombinase driven by the
rat albumin promoter [124]. In these KO mice, despite the severe COX
deﬁciency and liver pathology (increased transaminases, lipid accu-
mulation and decrease glycogen storage), hepatocytes that escaped
COX10 deletion had proliferated and restored complete liver function
and COX deﬁciency at a later age. The animals had a complete rever-
sion of all pathological phenotypes resulting on a normal life span.
In contrast, the progeny of the cross of two KO mice, those animals
homozygous for both the ﬂoxed allele and the Cre recombinase,
presented a more severe hepatopathy due to the higher expression of
the recombinase. The pathology included a higher number of COX
deﬁcient hepatocytes, hepatomegaly and microvesicular steatosis.
These mice died at around 2 months of age [124].
We also created two models of CNS speciﬁc COX deﬁcient mice. In
the ﬁrst model, the ablation of the ﬂoxed COX10 gene was driven by
the synapsin-1 promoter which is expressed early during embryonic
development by embryonic day 12.5 (E12.5). In the secondmodel, the
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lation of the CamKIIα promoter which produces a postnatal expres-
sion of Cre mainly in the hippocampus and cortex. The ﬁrst model will
be referred as the infantile and the second as the adult neuron speciﬁc
COX10 KO mice. The infantile COX10 KO mice did not show any gross
brain abnormalities and the COX deﬁciency in brain homogenates was
very mild (about 80% of control values) although they died at 10 days
of age (Diaz andMoraes, unpublished results). In spite of themild COX
deﬁciency observed and lack of gross brain abnormalities, further
characterization of this animal model is required. This will establish if
neurogenesis and cell differentiation of speciﬁc neuronal populations
is impaired by the lack of mitochondrial respiration. Neurons are
generated from neuronal progenitor cells before birth whereas the
majority of glia cells (astrocytes and oligodendrocytes) are generated
after birth (during the ﬁrst month of age) in the mammalian CNS.
During mouse brain development neurogenesis starts at E12 to E15
and ends at birth [125,126]. This period of neurogenesis coincides
with the expression of Cre recombinase in our infantile COX10 KO
mice. In addition, the COX defect may affect apoptosis and correct
balance of neuronal populations required during brain development.
The adult COX10 neuron speciﬁc deﬁcient mouse was phenotyp-
ically undistinguishable from control littermates until they reached 3.5
to 4 months of age when behavioral abnormalities became evident.
They presented with alternated hypo- and hyperactive episodes,
increased appetite, hypersensitivity to environmental noise and
aggressive behavior. Eventually as disease progressed, the animals
became more irresponsive. The behavioral phenotype was accompa-
nied by neuronal degeneration that started after 4 months of age and
resulted in a dramatic cortical atrophy by 8 months of age, followed by
death although some mice reached and passed 1 year of age [127].
Initial characterization of this model showed a progressive COX
deﬁciency in cortex and hippocampus homogenates in the KO mice
starting at 1 month of age. Gross inspection of brains at 4 months of
age did not show any apparent abnormalities or altered steady-state
levels of Tuj1, a neuronal marker [127]. Further examination of the
brain pathology in the COX10 KO mice revealed early molecular
neurodegeneration signs including the presence of tunel positive cells
and reactive astrocytes (increased GFAP expression) starting at
4 months of age (Diaz and Moraes, unpublished results). In the adult
COX10 KO model, neurons seem to survive for about 2 months from
the onset of the COX deﬁciency until ﬁrst signs of neurodegeneration
appeared. This same prolonged neuronal survival in the absence of
oxidative phosphorylation was previously observed in a conditional
KO for the mitochondrial transcription factor TFAM where all respi-
ratory complexes were impaired [128]. These results suggest that
neurons are capable ofmetabolically adapting (at least temporarily) to
the lack ofmitochondrial respiration. They possibly accomplish this by
upregulating other energy generating pathways such as glycolysis.
Numerous neurodegenerative disorders have been associatedwith
mitochondrial dysfunction, accumulation of mtDNA mutations and
oxidative damage. Particularly, in Alzheimer's disease (AD), numerous
investigators reported a reduction of COX activity [129] and increase in
oxidative damage in brain fromADpatients. In addition, recent reports
described mtDNA mutations including point mutations in COX
encoded subunits as well as mutations in regulatory regions of the
mtDNA in AD patients [130–133]. In an effort to expand our under-
standing of the implications of COX deﬁciency in AD, we crossed the
adult COX10 KO mouse with a previously established AD transgenic
mouse resulting in a COXdeﬁcient ADmouse (COXd/ADmouse) [127].
The AD mouse model used to accomplish this study expresses mutant
forms of bothAPP and presenilin that leads to the formation of amyloid
plaques, however this mouse does not developed cognitive abnor-
malities [134]. Unexpectedly, the COXd/AD mice had a reduced
number of amyloid plaques concomitant with a reduction in Aβ42
levels, reduction of β-secretase activity and reduction in oxidative
damage when compared with the AD mice at 4 months of age. In theAD transgenic model, damages caused by oxidative stress have been
associated to the pathology and accumulation of amyloid plaques.
Moreover, treatment of the ADmicewith antioxidants such as vitamin
E decreased accumulation of amyloid plaques and reduction of the
antioxidant mechanisms such as SOD2 increased the accumulation of
plaques [135,136]. Extensive analysis measuring ROS production,
protein carbonylation or nucleic acid oxidation failed to reveal any
oxidative damage induced by COX deﬁciency, on the contrary, all the
values obtained for the COXd/AD mice were signiﬁcantly lower than
the ones for the AD mice. Therefore, COX deﬁciency does not promote
the oxidative stress observed in AD but rather is a consequence of the
accumulation of Aβ in neurons [127].
7. Concluding remarks
In the last 10 years the understanding of COX biogenesis and its
regulation have taken a great forward leap albeit many unanswered
questions remain. The creation of numerous animalmodels thatmimic
the pathological conditions seen in humans are paving the way for the
development of new and alternative treatments for mitochondrial
diseases.
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